Cargando…

Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression

BACKGROUND & AIMS: Bulevirtide (BLV) is a novel antiviral drug licensed for the treatment of chronic hepatitis D. Data on the safety and efficacy of stopping BLV therapy upon long-term HDV-RNA suppression are scarce. METHODS: A total of seven patients (age, 31–68 years, four with cirrhosis) incl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jachs, Mathias, Panzer, Marlene, Hartl, Lukas, Schwarz, Michael, Balcar, Lorenz, Camp, Jeremy V., Munda, Petra, Mandorfer, Mattias, Trauner, Michael, Aberle, Stephan W., Zoller, Heinz, Reiberger, Thomas, Ferenci, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285645/ https://www.ncbi.nlm.nih.gov/pubmed/37360907 http://dx.doi.org/10.1016/j.jhepr.2023.100751

Ejemplares similares

Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study
por: Jachs, Mathias, et al.
Publicado: (2022)

Treatment of Chronic Hepatitis D with Bulevirtide—A Fight against Two Foes—An Update
por: Ferenci, Peter, et al.
Publicado: (2022)

Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center
por: Jachs, Mathias, et al.
Publicado: (2023)

Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression
por: Jachs, Mathias, et al.
Publicado: (2022)

Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis
por: Jachs, Mathias, et al.
Publicado: (2021)

Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV
por: Mateo, Roberto, et al.
Publicado: (2023)

Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients
por: Schmidbauer, Caroline, et al.
Publicado: (2021)

Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2022)

An impaired pituitary–adrenal signalling axis in stable cirrhosis is linked to worse prognosis
por: Hartl, Lukas, et al.
Publicado: (2023)

Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
por: Balcar, Lorenz, et al.
Publicado: (2021)

COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital
por: Pomej, Katharina, et al.
Publicado: (2021)

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Endoscopic band ligation is safe despite low platelet count and high INR
por: Pfisterer, Nikolaus, et al.
Publicado: (2023)

Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event
por: Balcar, Lorenz, et al.
Publicado: (2022)

The impact of COVID-19 on liver transplantation programs in Austria
por: Hartl, Lukas, et al.
Publicado: (2022)

Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients
por: Balcar, Lorenz, et al.
Publicado: (2023)

Imaging features facilitate diagnosis of porto-sinusoidal vascular disorder
por: Lampichler, Katharina, et al.
Publicado: (2022)

Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis
por: Hartl, Lukas, et al.
Publicado: (2022)

Gut-liver axis signaling in portal hypertension
por: Simbrunner, Benedikt, et al.
Publicado: (2019)

Recent advances in the understanding and management of hepatorenal syndrome
por: Simbrunner, Benedikt, et al.
Publicado: (2021)

Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19
por: Hartl, Lukas, et al.
Publicado: (2021)

Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2021)

The systemic and hepatic alternative renin–angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation
por: Hartl, Lukas, et al.
Publicado: (2023)

Non‐invasive diagnosis of cirrhosis and long‐term disease monitoring by transient elastography in patients with Wilson disease
por: Paternostro, Rafael, et al.
Publicado: (2020)

HCV hotline facilitates Hepatitis C elimination during the COVID‐19 pandemic
por: Hartl, Lukas, et al.
Publicado: (2022)

Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2020)

Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis
por: Bucsics, Theresa, et al.
Publicado: (2022)

Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR
por: Semmler, Georg, et al.
Publicado: (2021)

Intact plasma quantification of the large therapeutic lipopeptide bulevirtide
por: Sauter, Max, et al.
Publicado: (2021)

COVID‐19‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality
por: Hartl, Lukas, et al.
Publicado: (2021)

Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis
por: Hofer, Benedikt S., et al.
Publicado: (2022)

Incidence, phenotype and prognostic relevance of COVID-19-related liver injury across different age strata
por: Hartl, Lukas, et al.
Publicado: (2022)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
por: Steiner, Sebastian, et al.
Publicado: (2017)

Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon‐Free Therapy
por: Mandorfer, Mattias, et al.
Publicado: (2019)

Age‐adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID‐19 patients
por: Hartl, Lukas, et al.
Publicado: (2022)

Observations following discontinuation of long-term denosumab therapy
por: McClung, M. R., et al.
Publicado: (2017)

Non-invasive tests-based risk stratification: Baveno VII and beyond
por: Semmler, Georg, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a4titd2l9rpcvcenif1dd7uc49